This study suggests that Eu NPs-based CD151CD63 assays in combination with glycovariant of CEA and CA125 are more sensitive in distinguishing CRC patient’s serum from benign and healthy controls than conventional CEA biomarkers alone. The gene discussed is MUC16; the disease is colorectal carcinoma.